ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has licensed Sangamo Therapeutics’ gene therapy programs for hemophilia A, including SB-525, which is expected to enter the clinic this quarter. Sangamo will get $70 million up front plus milestone payments of up to $300 million. Pfizer is already partnered with Spark Therapeutics on a gene therapy for hemophilia B. Last year Pfizer spent $150 million to acquire Bamboo Therapeutics and its gene therapy manufacturing facility.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X